Oncology Segment, by Application to Account Largest Share in Epigenetics Market during 2025-2031

According to our new research study on "Epigenetics Market Forecast to 2031 - Global Analysis - by Products and Services, Application, Technology, and End User," the market was valued at US$ 1,85 billion in 2024 to US$ 2.53 billion by 2031; the market is expected to register a CAGR of 4.7% during 2025-2031. The epigenetics market growth is attributed to the rising global prevalence of cancer, advancements in epigenetic technologies, and the expanding role of personalized medicine.

Continuously epigenetic technologies developments at a fast pace are the major forces behind the growth of the epigenetics market, which now offers extremely detailed analyses and very accurate modifications, thus greatly extending the range of research and therapeutic applications. One of such technology is the creation of the CRISPR-dCas9 fused with epigenetic effectors, which allows targeted histone acetylation or DNA demethylation without changing the genome sequence, with an efficiency of up to 70% in gene reactivation in disease models. For example, in breast cancer models, chromatin reprogramming via CRISPR-Cas9 epigenetic editing led to tumor growth being inhibited by 50% in preclinical studies. Moreover, methodologies for sequencing have significantly improved; single-cell ATAC-seq and bisulfite sequencing now localize chromatin accessibility and methylation at a single-nucleotide level and are less expensive and faster for large sample cohorts.

AI is very helpful in CRISPR design, such that AI can predict off-target effects to a 90% accuracy level, thus facilitating the rapid gene therapy development process for such diseases as sickle cell disease. As of 2025, more than 50 CRISPR clinical trials have epigenetic components, and they are mainly focused on cancers and genetic disorders. In colorectal cancer, UHRF1 inhibitors, which have been pinpointed by advanced screening methods, are causing the reversal of epigenetic silencing in solid tumors, hence they are very effective in therapy-resistant regions.

PubMed records indicate a growing trend with regard to epigenetics, with 21,699 entries in epigenetic epidemiology alone by 2023, and the yearly output across the field tops 20,000. Temporary delivery vehicles, for example, mRNA-based CRISPR editors, can perform in vivo epigenetic modulation in liver pathologies and thus are able to achieve the restoration of gene expression with 80-85% specificity in animal models. Also, these devices are instrumental in the multi-omics strategy, where epigenomics and transcriptomics were combined to discover more than 200 new targets for neurodegenerative diseases.

In the treatment of HIV, silent integration of latent reservoirs through epigenetic reactivation using CRISPR has led to viral clearance in 60% of infected cell lines. Such advancements have resulted in the formation of collaborations, with academic and clinical bodies moving closer to obtaining the green light from the regulatory authorities, as is the case with epigenetic modulators entering phase III trials for leukemia. All these breakthroughs in technology have made epigenetics more widely accessible, thereby opening new global research opportunities and regenerative potentials for aging and chronic diseases.

Based on products and services, the epigenetics market is segmented into kits and reagents, instruments and accessories, enzymes, and services. In 2024, the kits and reagents segment held a significant epigenetics market share. The segment forms the backbone of the epigenetic technologies market, enabling precise analysis of gene expression modifications such as DNA methylation, histone acetylation, and chromatin remodeling without altering the underlying DNA sequence, driven by surging demand for tools that enable precise analysis of epigenetic modifications. This segment is pivotal for both research and diagnostic applications, particularly in oncology, neurology, and personalized medicine, where epigenetic biomarkers aid in early disease detection and targeted therapies. High-quality reagents and kits are crucial for accurate and reliable epigenetic analysis and research in academic, clinical, and industrial settings. Kits include bisulfite conversion kits for methylation profiling, ChIP-sequencing kits for histone studies, and RNA sequencing kits for transcriptomic insights. Reagents are crucial in antibody binding, supporting analytical processes, and synthesizing targeted molecules. They are available in various grades, each tailored for specific applications and possessing distinct properties. In epigenetics, reagents are essential for activities, including DNA methylation, RNA transcription, histone modification, DNA purification, PCR, and assays. QIAGENs EpiTect Bisulfite Kits are widely used for quantitative methylation analysis in cancer research, and Thermo Fisher Scientifics histone modification antibodies and reagents support high-throughput assays.

Various reagent suppliers are gaining significant traction amid rising tariffs and supply?chain concerns. In August 2025, Reuters reported that Chinese pharma research and development firms are sourcing reagents from domestic players, driven by cost pressures, supply reliability needs, and tariffs that peaked at 125% in April 2025. Domestic reagents offer lower cost, faster delivery, and reduced exposure to tariff risk, key in fast?paced research and development environments. Western multinationals such as Merck, Roche, and Thermo Fisher respond by expanding local production facilities in various countries.

Based on application, the market is bifurcated into oncology and non-oncology. The oncology segment held the largest epigenetics market share in 2024, and the same segment is estimated to register the higher CAGR during 2025-2031. Shifting Cancer Incidence Rates Resulted from Aging Population, Urban Lifestyles, and Environmental Factors to Which Only More Precise, Personalized, and Early Diagnostic Tools Can Respond Are Widely Sought in Cancer Research and Management. A significant part of the aforementioned tools is epigenetic-technologies, in which DNA methylation and histone modification have become the most widely studied ones. Epigenetics is recognized as a potential source of the problem solution because it can identify gene expression changes without affecting the DNA sequence. The use of epigenetic biomarkers for early cancer diagnosis and prognosis has set a trend in this field. The tests based on DNA methylation are applied in detecting cancer at its early stage of colorectal and lung cancer via non-invasive liquid biopsy.

In June 2023, BGI Genomics exclusive methylation DNA-based cancer screening test, COLOTECT - the DNA Methylation Detection Kit for Human SDC2, ADHFE1, and PPP2R5C Genes (Real-time PCR) -, was officially registered on the Australian Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA), the regulatory authority in Australia. COLOTECT offers non-invasive colorectal cancer screening in adults aged 45-74 with a high level of sensitivity and is a good alternative to the Guaiac Fecal Occult Blood Test and the Immunochemical Fecal Occult Blood Test methods. Thanks to advanced DNA methylation detection, COLOTECT makes it possible to detect colorectal cancer and precancerous lesions at the earliest stage with higher accuracy. By targeting specific methylation patterns, healthcare providers can locate early-stage colorectal cancer and predict the chances of the disease advancing, thus intervention at the right time and personalized treatment strategies will be facilitated.

Promega Corp, Abcam Plc, Oxford Nanopore Technologies, QIAGEN NV, Thermo Fisher Scientific Inc., Merck KGaA, Revvity Inc., Active Motif, EpiGentek Group Inc., and Agilent Technologies Inc. are among the leading companies operating in the global epigenetics market.

Companies operating in the epigenetics market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the epigenetics market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall epigenetics market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com